A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Leslie, Toby ^a,b   Mayan, Ismail ^b   Mohammed, Nasir ^b   Erasmus, Panna ^b   Kolaczinski, Jan ^a   Whitty, Christopher J M ^a   Rowland, Mark ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Department of Research and Development   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PLACEBO; PRIMAQUINE; ANTIMALARIAL AGENT; HEMOGLOBIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; PAKISTAN; PLASMODIUM VIVAX; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT RESPONSE; AGED; DISEASE TRANSMISSION; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; RECURRENT DISEASE; SAFETY;

PLASMODIUM VIVAX;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; MALARIA, VIVAX; MALE; MIDDLE AGED; PAKISTAN; PLACEBOS; PRIMAQUINE; RECURRENCE; SAFETY;

EID: 51349090051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002861     Document Type: Article

References (31)

1. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med & Hyg, 64,(1-2 suppl): 97-106. 2001.
2. Hay C, Guerra A, Tatem A, Noor R, Snow R (2005) The global distribution and population at risk of malaria: past, present, and future. Lancet Inf Dis, 4(6): 327-336 S.
3. Barcus MJ, Basri H, Picarima H, Manyakuri C, Sekaruti, et al. (2007) Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in North-eastern Indonesian Papua. Am. J. Trop. Med. Hyg. 75(5): 984-991.
4. Sachs J, Malaney P (2002) The economic and social burden of malaria. Nature, 415 (6672): 680-685.
5. Garnham PCC (1998) Hypnozoites and relapses in Plasmodium vivax and in vivax-like malaria. Tropical & Geographical Medicine, 40: 187-195.
6. Rowland M, Nosten F (2001) Malaria epidemiology and control in refugee camps and complex emergencies. Ann Trop Med Para, 95: 741-754.
7. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, et al. (2004) Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Tran R Soc Trop Med Hyg. 98(3): 168-73.
8. Rowland M, Mohammed N, Rehman H, Hewitt S, Mendis C (2002) Anopheline vectors and malaria transmission in eastern Afghanistan. Tran R Soc Trop Med Hyg. 96(6): 620-6.
9. Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, et al. (1995) Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programs. Tran R Soc Trop Med Hyg, 89: 62-64.
10. Ali N, Anwar M, Ayyub M, Bhatti FA, Nadeem M (2005) Frequency of glucose-6-phosphate hydrogenase deficiency in some ethnic groups of Pakistan. J Coll Physicians Surg Pak. 15(3): 137-41.
11. WHO (2006) Guidelines for the treatment of malaria. World Health Organisation. pp 64.
12. WHO (1990) Practical Chemotherapy of Malaria. Geneva: World Health Organisation, Technical Report Series, no.805..
13. Rowland M, Durrani N (1999) Randomised controlled trial of 5 and 14 day primaquine therapy against relapses of malaria in an Afghan refugee settlement in Pakistan. Tran R Soc Trop Med Hyg. 93: 642-643.
14. Gogtay NJ, Desai S, Kamtekar KD, Kadam VS, Dalvi SS, et al. (1999) Efficacies of 5 and 14 day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. Ann Trop Med Parasitol 93: 809-812.
15. Galappaththy GNL, Omari AAA, Tharyan P (2007) Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2007, Issue 1.; Art. No.: CD004389. DOI: 10.1002/ 14651858.CD004389.pub2.
16. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW (1960) Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO 22: 621-631.
17. Brewer GJ, Zarafonetis CJD (1967) The Haemolytic effect of various regimens with primaquine and chloroquine in American Negroes with G6PD deficiency and the lack of an effect of various antimalarial suppressive agents on erythrocyte metabolism. Bull WHO. 36: 303-308.
18. Bolchoz LJC, Budinski RA, McMillan DC, Jollow DJ (2001) Primaquine induced haemolytic anaemia: Formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. J Pharmacol Exp Ther. 297(2): 509-515.
19. Baird JK (2007) A rare glimpse at the efficacy of primaquine. Am J Trop Med Hyg. 76(2): 201-2.
20. Fletcher KA, Barton PF, Kelly JA (1988) Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem Pharmacol. 37(13): 2683-2690.
21. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, et al. (1985) Pharmacokinetics of Primaquine in man I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmac. 19: 745-750.
22. Clyde DF (1981) Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull WHO. 59(3): 391-395.
23. Goller JL, Jolley D, Ringwald P, Biggs B (2007) Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 76(2): 203-207.
24. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, et al. (2007) Relapse of Plasmodium vivax infection usually result from the activation of heterologous hypnozoites. JID. 195: 927-933.
25. Ajdukiewicz KM, Ong EL (2006) Management of vivax malaria with low sensitivity to primaquine. J Infect. Abstract. E Publication. 2006..
26. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y (1997) Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol 91: 939-943.
27. Leslie T, Mayan I, Hasan MA, Safi MH, Klinkenberg E (2007) Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: A randomized control trial. JAMA. 297(20): 2201-9.
28. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E (2007) Chloroquine resistant Plasmodium vivax: in vitro characteristics and association with molecular polymorphisms. PLoS ONE. 10: e1089.
29. Krudsood S, Tangpudee N, Wailaratana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S (2008) High-dose Primaquine Regimens against Relapse of Plasmodium vivax Malaria. Am J Trop Med Hyg, 78(5): 736-740.
30. Yeung S, White NJ (2005) How do patients use antimalarial drugs? A review of the evidence. Top Med Int Health. 10(2): 121-138.
31. Roberts L, Enserink M (2007) Did they really say... eradication? Science. 318(5856): 1544-5.